All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
SB 211475
Known as:
SB-211475
Â
Â
National Institutes of Health
Watch Topic
Topic mentions per year
Topic mentions per year
1994-1998
0
1
2
1994
1998
Related topics
Related topics
2 relations
Broader (2)
Carbazoles
Propanolamines
Related mentions per year
Related mentions per year
1938-2018
1940
1960
1980
2000
2020
SB 211475
Carbazoles
Propanolamines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits.
H Brunvand
,
Gui Lin Liu
,
Xin-liang Ma
,
Tian-li Yue
,
Robert R. Ruffolo
,
Giora G Z Feuerstein
European journal of pharmacology
1998
The aim of this study was to investigate the effect of SB 211475, a metabolite of carvedilol with weak alpha1-adrenoceptor…Â
(More)
Is this relevant?
1998
1998
Effects of a hydroxylated metabolite of the beta-andrenoreceptor antagonist, carvedilol, on post-ischaemic splachnic tissue injury.
Theodore A. Christopher
,
Bernard L. Lopez
,
Xin-liang Ma
,
Giora G Z Feuerstein
,
Robert R. Ruffolo
,
Tian-li Yue
British journal of pharmacology
1998
1 Reactive oxygen species have been demonstrated to play a critical role in post-ischaemic tissue injury. The present experiment…Â
(More)
Is this relevant?
1994
1994
SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant.
Tian-li Yue
,
P J Mckenna
,
+4 authors
Giora G Z Feuerstein
European journal of pharmacology
1994
The antioxidant effects of SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, were studied and compared with…Â
(More)
Is this relevant?